MDCG2020-10∕1修订版1 《欧盟法规(EU)2017745》下医疗器械临床研究中的安全性报告
MDCG 2020-10/1 1
EU2017/745
2022 10
2017/745 103 MDCGMDCG
Page 1 of 19
5.1
9.4
5.2.2
10.2.1
4
5
10.2.19 - 20
10.2.15 17
MDCG 2020-10/1 1
Page 2 of 19
May 2020
MDCG 2020-10 Rev 1
Safety reporting in clinical investigations
of medical devices under the Regulation (EU) 2017/745
1 ............................................................................................................................................................................................................................................................................................................ 3
1.1 EUDAMED ...................................................................................................................................................................................................................................................................3
2 ............................................................................................................................................................................................................................................................................................................ 4
2.1 ............................................................................................................................................................................................................................................................................................................4
2.2 ..................................................................................................................................................................................................................................................................4
3 ............................................................................................................................................................................................................................................................................................................ 5
3.1 ........................................................................................................................................................................................................................................................................................5
3.2 AE ............................................................................................................................................................................................................................................................................ 5
3.3 SAE .................................................................................................................................................................................................................................................................. 5
3.4 ............................................................................................................................................................................................................................................................................................5
4 ..................................................................................................................................................................................................................................................................................................... 6
4.1 EUDAMED .............................................................................................................................................................................................................................................................................6
4.2 NCAS ......................................................................................................................................................................................................................................................................6
4.3 ........................................................................................................................................................................................................................................................................................................6
5 ............................................................................................................................................................................................................................................................................................... 7
5.1 74.1 PMCF ............................................................................................................................................................................................................7
5.2 .............................................................................................................................................................................................................................................................7
5.3 ..........................................................................................................................................................................................................................................7
5.4 PMCF ......................................................................................................................................................................................................................................8
6 ........................................................................................................................................................................................................................................................................................ 8
7 .................................................................................................................................................................................................................................................................................................... 8
8 ............................................................................................................................................................................................................................................................................................... 8
8.1 NCAS .............................................................................................................................................................................................................................................................................................8
8.2 ................................................................................................................................................................................................................................................................................................9
9 ............................................................................................................................................................................................................................................................................................ 9
10 .................................................................................................................................................................................................................................................................................................. 11
10.1 ................................................................................................................................................................................................................................................................................11
10.2 ........................................................................................................................................................................................................................................................................13
11 .................................................................................................................................................................................................................................................................................................. 16
12 ...................................................................................................................................................................................................................................................... 16
Page 3 of 19
摘要：
展开>>
收起<<
MDCG2020101OrH10kvlEU20177450NSuVhhN4xzvNvQhbTJ2022t10ggeNu1kv2017745Sl103gazvSuVhhSOMDCGS0MDCGu1bgbTXVvNhbu1kvYTXOvNTNhbNN0eNvkm2YTXOeNNNSfkm2YTXOvezW0geNNhvNOUpWGNQwglgRSgkm2TvlbYkvlOQQwggRv0Page1of19evxNR5194onon522102145hhQS10219201021517eNIMDCG2020101OrH1vSfQsNbTJLvfQsNXkQbTJhvffePage2of19May20...
声明：如果您的权利被侵害，请联系我们的进行举报。
相关推荐
-
GB∕T 25915.2-2021 洁净室及相关受控环境 第2部分：洁净室空气粒子浓度的监测
2024-04-17 999+ -
GB∕T 25915.3-2024洁净室及相关受控环境 第3部分：检测方法VIP免费
2024-08-09 127 -
（高清)GB∕T 25915.3-2024 洁净室及相关受控环境第3部分：检测方法VIP免费
2025-08-27 999+ -
GB∕T 16886.1-2025医疗器械生物学评价 第1部分 风险管理过程中生物学安全性评价的要求和通用原则（草案稿）VIP免费
2025-09-02 833 -
GB∕T 16886.11-2021 医疗器械生物学评价 第11部分：全身毒性试验VIP免费
2025-09-02 865 -
GB∕T 191-2025 包装储运图示标志（征求意见稿）VIP免费
2025-09-29 999+ -
GB∕T 19000-2016 质量管理体系 基础和术语（高清）VIP免费
2025-10-27 999+ -
GB∕T 19001-2016 质量管理体系要求
2025-10-27 999+ -
GB∕T 16292-2025 医药工业洁净室（区）悬浮粒子的测试方法VIP免费
2025-10-29 999+ -
GB∕T 16292《医药工业洁净室（区）悬浮粒子的测试方法》2010版和2025版对比分析（逐条对比）VIP免费
2025-10-30 579
作者：一如既往
分类：法规规范
价格：100质量币
属性：19 页
大小：3.03MB
格式：PDF
时间：2026-03-17
